Who are ropivacaine mixed with dexmedetomidine's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ropivacaine-mixed-with-dexmedetomidine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

ropivacaine mixed with dexmedetomidine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ropivacaine mixed with dexmedetomidine (ropivacaine mixed with dexmedetomidine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic combination with alpha-2 adrenergic agonist. Area: Anesthesia and Pain Management.

marketed Local anesthetic combination with alpha-2 adrenergic agonist Voltage-gated sodium channels (ropivacaine); alpha-2 adrenergic receptors (dexmedetomidine) Anesthesia and Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

ropivacaine mixed with dexmedetomidine (ropivacaine mixed with dexmedetomidine) — The First Hospital of Qinhuangdao. Ropivacaine blocks sodium channels to provide local anesthesia, while dexmedetomidine activates alpha-2 adrenergic receptors to enhance analgesia and sedation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ropivacaine mixed with dexmedetomidine TARGET	ropivacaine mixed with dexmedetomidine	The First Hospital of Qinhuangdao	marketed	Local anesthetic combination with alpha-2 adrenergic agonist	Voltage-gated sodium channels (ropivacaine); alpha-2 adrenergic receptors (dexmedetomidine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic combination with alpha-2 adrenergic agonist class)

The First Hospital of Qinhuangdao · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ropivacaine mixed with dexmedetomidine — Competitive Intelligence Brief. https://druglandscape.com/ci/ropivacaine-mixed-with-dexmedetomidine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab